Skip to main content
Erschienen in: Journal of General Internal Medicine 7/2015

01.07.2015 | Original Research

Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program

verfasst von: Stacey B. Trooskin, MD PhD, Joanna Poceta, BA, Caitlin M. Towey, MPH, Annajane Yolken, BS, Jennifer S. Rose, PhD, Najia L. Luqman, MPH, Ta-Wanda L. Preston, BA, Philip A. Chan, MD MS, Curt Beckwith, MD, Sophie C. Feller, BA, Hwajin Lee, BS, Amy S. Nunn, MS ScD

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

ABSTRACT

BACKGROUND

Many of the five million Americans chronically infected with hepatitis C (HCV) are unaware of their infection and are not in care.

OBJECTIVE

We implemented and evaluated HCV screening and linkage-to-care interventions in a community setting.

DESIGN

We developed a comprehensive, community-based HCV screening and linkage-to-care program in a medically underserved neighborhood with high rates of HCV infection in Philadelphia, Pennsylvania. We provided patient navigation services to enroll uninsured patients in insurance programs, facilitate referrals from primary care physicians and link patients to an HCV infectious disease specialist with intention to treat and cure.

PATIENTS

Philadelphia residents were recruited through street outreach.

MAIN MEASURES

We measured anti-HCV seroprevalence and diagnosis, linkage and retention in care outcomes for chronically infected patients.

KEY RESULTS

We screened 1,301 participants for HCV; anti-HCV seroprevalence was 3.9 % and 2.8 % of all patients were chronically infected. Half of chronically infected patients were newly diagnosed; the remaining patients were aware of infection but not in care. We provided confirmatory RNA testing and results, assisted patients with attaining insurance and linked most chronically infected patients to a primary care provider. The biggest barrier to retaining patients in care was obtaining referrals for subspecialty providers; however, we obtained referrals for 64 % of chronically infected participants and have retained most in subspecialty HCV care. Several have commenced treatment.

CONCLUSIONS

Non-clinical screening programs with patient navigator services are an effective means to diagnose, link, retain and re-engage patients in HCV care. Eliminating referral requirements for subspecialty care might further enhance retention in care for patients chronically infected with HCV.
Literatur
1.
Zurück zum Zitat Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.PubMedCrossRef Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.PubMedCrossRef
2.
Zurück zum Zitat Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090–101. Epub 2011 Mar 15.PubMedCrossRef Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090–101. Epub 2011 Mar 15.PubMedCrossRef
3.
Zurück zum Zitat Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate [Abstract #44]. Oral presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (Boston) 2005. Hepatology. 2005;42(4 Suppl 1):213A. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate [Abstract #44]. Oral presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (Boston) 2005. Hepatology. 2005;42(4 Suppl 1):213A.
4.
5.
Zurück zum Zitat Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedCrossRef Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedCrossRef
6.
Zurück zum Zitat Singal AG, Volk ML, Jensen D, Di Bisceqlie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8. Epub 2009 Nov 27.PubMedCrossRef Singal AG, Volk ML, Jensen D, Di Bisceqlie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8. Epub 2009 Nov 27.PubMedCrossRef
7.
Zurück zum Zitat Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61. Epub 2012 Apr 10.PubMedCrossRef Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55(6):1652–61. Epub 2012 Apr 10.PubMedCrossRef
8.
Zurück zum Zitat Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. 2012;17;61(RR04):1–18. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. 2012;17;61(RR04):1–18.
9.
Zurück zum Zitat Denniston MM, Jiles RB, Drobenius J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic Hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.PubMedCrossRef Denniston MM, Jiles RB, Drobenius J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic Hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.PubMedCrossRef
10.
Zurück zum Zitat Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366(3):273–5.PubMedCrossRef Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366(3):273–5.PubMedCrossRef
11.
Zurück zum Zitat Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.PubMedCentralPubMedCrossRef Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.PubMedCrossRef Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.PubMedCrossRef
13.
Zurück zum Zitat Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clin Gastroenterol Hepatol. 2014;12(5):728–737. Epub 2013 Jul 18.PubMedCentralPubMedCrossRef Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clin Gastroenterol Hepatol. 2014;12(5):728–737. Epub 2013 Jul 18.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med. 2014;370(17):1576–8.PubMedCrossRef Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med. 2014;370(17):1576–8.PubMedCrossRef
15.
Zurück zum Zitat Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–70.PubMedCrossRef Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263–70.PubMedCrossRef
16.
Zurück zum Zitat Centers for Disease Control and Prevention. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005–2011. 2013;10;62(18):357–61. Centers for Disease Control and Prevention. Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005–2011. 2013;10;62(18):357–61.
17.
Zurück zum Zitat Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.PubMedCrossRef Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.PubMedCrossRef
18.
Zurück zum Zitat Centers for Disease Control and Prevention. Locations and reasons for initial testing for hepatitis C infection - chronic hepatitis cohort study, United States, 2006–2010. 2013;62(32):645–8. Centers for Disease Control and Prevention. Locations and reasons for initial testing for hepatitis C infection - chronic hepatitis cohort study, United States, 2006–2010. 2013;62(32):645–8.
19.
Zurück zum Zitat Beckwith CG, Kurth A, Bazerman L, Solomon L, Patry E, Rich JD, Kuo I. HCV Testing in correctional facilities: a routine testing recommendation is urgently needed. Am J Public Health. Forthcoming 2014. Beckwith CG, Kurth A, Bazerman L, Solomon L, Patry E, Rich JD, Kuo I. HCV Testing in correctional facilities: a routine testing recommendation is urgently needed. Am J Public Health. Forthcoming 2014.
20.
Zurück zum Zitat Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14:74.PubMedCentralPubMedCrossRef Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14:74.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.PubMedCrossRef Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.PubMedCrossRef
22.
Zurück zum Zitat Martin NK, Hickman MN, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8). Martin NK, Hickman MN, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8).
23.
Zurück zum Zitat Fusfeld L, Aggarwal J, Dougher C, Vera-Lonch M, Bubb S, Donepudi M, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13:234.PubMedCentralPubMedCrossRef Fusfeld L, Aggarwal J, Dougher C, Vera-Lonch M, Bubb S, Donepudi M, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13:234.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24(12):753–62.PubMedCrossRef Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24(12):753–62.PubMedCrossRef
25.
Zurück zum Zitat Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103(10):e81–8.PubMedCentralPubMedCrossRef Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103(10):e81–8.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, et al. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58(5):890–7.PubMedCrossRef Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, et al. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58(5):890–7.PubMedCrossRef
27.
Zurück zum Zitat Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207(Suppl 1):S19–25.PubMedCentralPubMedCrossRef Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207(Suppl 1):S19–25.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Moorman AC, Gordon SC, Rupp LB, Spradling PR, Tashale EH, Lu M, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56(1):40–50.PubMedCrossRef Moorman AC, Gordon SC, Rupp LB, Spradling PR, Tashale EH, Lu M, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56(1):40–50.PubMedCrossRef
29.
Zurück zum Zitat Cachay ER, Hill L, Wyles DL, Torriani FJ, Ballard C, Colwell B, et al. The hepatitis C cascade of care among HIV infected patients following diagnosis of HCV infection [Abstract 672]. Top Antivir Med. 2014;22(e-1):335. Cachay ER, Hill L, Wyles DL, Torriani FJ, Ballard C, Colwell B, et al. The hepatitis C cascade of care among HIV infected patients following diagnosis of HCV infection [Abstract 672]. Top Antivir Med. 2014;22(e-1):335.
30.
Zurück zum Zitat Yehia BR, Schranz AJ, Umscheid CA, Lo Re III V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systemic review and meta-analysis. PLoS ONE. 2014;9(7):e101554–e101554.PubMedCentralPubMedCrossRef Yehia BR, Schranz AJ, Umscheid CA, Lo Re III V. The treatment cascade for chronic hepatitis C virus infection in the United States: A systemic review and meta-analysis. PLoS ONE. 2014;9(7):e101554–e101554.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20(11):745–60.PubMedCentralPubMed Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20(11):745–60.PubMedCentralPubMed
32.
Zurück zum Zitat Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126–33.PubMedCentralPubMedCrossRef Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126–33.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Ditah IC, Ngwa T, Ditah CM, Ewelukwa O, Kamath PS. Bridging the gap between HCV screening and access to necessary care: National Health and Nutrition Examination Survey HCV follow-up, 2001–2010 [Su1027]. Gastroenterology. 2014;146(5 Suppl 1):S-966.CrossRef Ditah IC, Ngwa T, Ditah CM, Ewelukwa O, Kamath PS. Bridging the gap between HCV screening and access to necessary care: National Health and Nutrition Examination Survey HCV follow-up, 2001–2010 [Su1027]. Gastroenterology. 2014;146(5 Suppl 1):S-966.CrossRef
34.
Zurück zum Zitat Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLOS One. 2014;9(5):e97317.PubMedCentralPubMedCrossRef Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLOS One. 2014;9(5):e97317.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Trooskin SB, Hadler J, St Louis T, Navarro VJ. Geospatial analysis of hepatitis C in Connecticut: a novel application of a public health tool. Public Health. 2005;119(11):1042–7.PubMedCrossRef Trooskin SB, Hadler J, St Louis T, Navarro VJ. Geospatial analysis of hepatitis C in Connecticut: a novel application of a public health tool. Public Health. 2005;119(11):1042–7.PubMedCrossRef
36.
Zurück zum Zitat Astell-Burt T, Flowerdew R, Boyle P, Dillon J. Is travel-time to a specialist center a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Soc Sci Med. 2012;75(1):240–7. Astell-Burt T, Flowerdew R, Boyle P, Dillon J. Is travel-time to a specialist center a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Soc Sci Med. 2012;75(1):240–7.
37.
Zurück zum Zitat Astell-Burt T, Flowerdew R, Boyle PJ, Dillon JF. Does geographic access to primary healthcare influence the detection of hepatitis C? Soc Sci Med. 2011;72(9):1472–81.PubMedCrossRef Astell-Burt T, Flowerdew R, Boyle PJ, Dillon JF. Does geographic access to primary healthcare influence the detection of hepatitis C? Soc Sci Med. 2011;72(9):1472–81.PubMedCrossRef
38.
Zurück zum Zitat Monnet E, Ramée C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med. 2008;66(5):1046–56.PubMedCrossRef Monnet E, Ramée C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med. 2008;66(5):1046–56.PubMedCrossRef
39.
Zurück zum Zitat Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53(3):737–45.PubMedCrossRef Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53(3):737–45.PubMedCrossRef
40.
Zurück zum Zitat Searson G, Engelson SE, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int. 2014;34(5):668–71.PubMedCrossRef Searson G, Engelson SE, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int. 2014;34(5):668–71.PubMedCrossRef
41.
Zurück zum Zitat Nunn A, Yolken A, Cutler B, Trooskin S, Wilson P, Little S, et al. Geography Should Not Be Destiny: Focusing HIV/AIDS Implementation Research and Programs on Microepidemics in US Neighborhoods. Am J Public Health. 2014;104(5):775–80.PubMedCentralPubMedCrossRef Nunn A, Yolken A, Cutler B, Trooskin S, Wilson P, Little S, et al. Geography Should Not Be Destiny: Focusing HIV/AIDS Implementation Research and Programs on Microepidemics in US Neighborhoods. Am J Public Health. 2014;104(5):775–80.PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Meyers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios AR, Sweeney MM, et al. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. J Acquir Immune Defic Syndr. 2012;61(1):23–31.CrossRef Meyers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios AR, Sweeney MM, et al. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. J Acquir Immune Defic Syndr. 2012;61(1):23–31.CrossRef
43.
Zurück zum Zitat Tohme RA, Xing J, Liao Y, Holmberg SD. Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009–2010. Am J Public Health. 2013;103(1):112–9.PubMedCentralPubMedCrossRef Tohme RA, Xing J, Liao Y, Holmberg SD. Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009–2010. Am J Public Health. 2013;103(1):112–9.PubMedCentralPubMedCrossRef
44.
45.
Zurück zum Zitat Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, et al. Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer. 2008;113(8):1999–2010.PubMedCentralPubMedCrossRef Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E, et al. Patient Navigation Research Program. Patient navigation: state of the art or is it science? Cancer. 2008;113(8):1999–2010.PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Vargas RB, Cunningham WE. Evolving trends in medical care-coordination for patients with HIV and AIDS. Curr HIV/AIDS Rep. 2006;3(4):149–53.PubMedCrossRef Vargas RB, Cunningham WE. Evolving trends in medical care-coordination for patients with HIV and AIDS. Curr HIV/AIDS Rep. 2006;3(4):149–53.PubMedCrossRef
47.
Zurück zum Zitat Ferrante JM, Winston DG, Chen P-H, de la Torre AN. Family physicians’ knowledge and screening of chronic hepatitis and liver cancer. Fam Med. 2008;40(5):345–51.PubMed Ferrante JM, Winston DG, Chen P-H, de la Torre AN. Family physicians’ knowledge and screening of chronic hepatitis and liver cancer. Fam Med. 2008;40(5):345–51.PubMed
48.
Zurück zum Zitat Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377–83.PubMedCrossRef Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377–83.PubMedCrossRef
49.
Zurück zum Zitat Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: Role of race and ethnicity. World J Gastroenterol. 2007;13(7):1074–10.PubMedCentralPubMedCrossRef Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: Role of race and ethnicity. World J Gastroenterol. 2007;13(7):1074–10.PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.PubMedCrossRef Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.PubMedCrossRef
51.
Zurück zum Zitat Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, et al. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model – Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393–8.PubMed Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, et al. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model – Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393–8.PubMed
52.
Zurück zum Zitat Stockman LA, Guilfoyle SM, Benoit AL, Vergeront JM, Davis JP. Rapid hepatitis C testing among persons at increased risk for infection – Wisconsin, 2012–2013. MMWR Morb Motal Wkly Rep. 2014;63(14):309–311. Stockman LA, Guilfoyle SM, Benoit AL, Vergeront JM, Davis JP. Rapid hepatitis C testing among persons at increased risk for infection – Wisconsin, 2012–2013. MMWR Morb Motal Wkly Rep. 2014;63(14):309–311.
Metadaten
Titel
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program
verfasst von
Stacey B. Trooskin, MD PhD
Joanna Poceta, BA
Caitlin M. Towey, MPH
Annajane Yolken, BS
Jennifer S. Rose, PhD
Najia L. Luqman, MPH
Ta-Wanda L. Preston, BA
Philip A. Chan, MD MS
Curt Beckwith, MD
Sophie C. Feller, BA
Hwajin Lee, BS
Amy S. Nunn, MS ScD
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 7/2015
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3209-6

Weitere Artikel der Ausgabe 7/2015

Journal of General Internal Medicine 7/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.